Abstract: Renal fibrosis is a common end-stage pathological manifestation of chronic kidney disease
(CKD), and its severity is closely related to the prognosis of CKD. In recent years, some studies have found
that erythropoietin (EPO) is closely associated with the occurrence and development of renal fibrosis. As a regulator of red blood cell production, exogenous EPO supplementation can not only improve renal anemia, but
also improve renal function and effectively prevent and treat renal fibrosis. Therefore, this paper reviews the
role of EPO in renal fibrosis and its anti-fibrosis mechanism, providing new ideas for the application of EPO
in the treatment of renal fibrosis in the future.

Key words: Erythropoietin, Renal fibrosis, renal EPO-producing cells, EPOR receptor